1910 Genetics

Today we announced a groundbreaking five-year commercial agreement and go-to-market collaboration with Microsoft to build the infrastructure layer for drug discovery using #AI and high performance computing.   This first of its kind, fully integrated, drug discovery and development platform will combine 1910’s massive, computational and wet lab biological data, robotics-driven laboratory automation and multimodal AI models for drug discovery with Microsoft’s next-generation high-performance computing platform, Azure Quantum Elements.   The platform will be offered to potential pharmaceutical, biotechnology, government, academic, and research institutions via three partnership models: Co-discovery, Co-engineering, and Platform-as-a-Service.   Together we will accelerate scientific discovery and empower pharmaceutical R&D teams worldwide to generate therapeutics faster and more cost-effectively. Press Release: https://lnkd.in/eHwmiNXH Customer Sign-up Form: https://lnkd.in/ek9dbk3T 

Congratulations to Jesse W. Collins, Ph.D., Mahmoud Ebrahimkhani, Ph.D., and Matthew Sherman on their well-deserved promotions! Your grit, drive, and many contributions to 1910 continue to help drive our success. Cheers to reaching new heights together! #AIInnovation #1910Genetics #Teamwork #CareerGrowth

Today, our Founder & CEO, Jen Nwankwo, Ph.D., will join our partner and Technology Advisory Board member, Cecil Lynch, Accenture Global Biomedical Informatics Lead, along with EDA Program Officer Amanda Kosty, NIH Office of Special Initiatives Deputy Director, Geetha S., and FDA Office of Strategic Programs Deputy Director, Jose Galvez, at the National ROADMAP Summit, hosted by the U.S. National Science Foundation in collaboration with the Economic Development Administration. Together, they’ll explore how to bridge the gap between start-ups and drug discovery, including how 1910 is leveraging state-of-the-art technology like AI to break down barriers in data, model, and computing power to accelerate drug discovery and development. Learn more about this exciting event here: https://bit.ly/3OAIVeH

1910 Genetics is excited to co-host the Boston stop of the Founder-led Biotech Tour with Pillar VC on Wednesday, November 20th. This multi-city event is a curated evening of networking with leaders of the founder-led biotech movement. Our Founder & CEO, Jen Nwankwo, Ph.D., will share her journey founding and scaling 1910 Genetics, and preview some of our upcoming milestones for 2025. Learn more or register here: https://bit.ly/48GWjas

Don’t miss 1910 Founder & CEO, Jen Nwankwo, Ph.D., discuss how 1910 is leveraging our groundbreaking end-to-end Input-Transform-Output (ITO™) platform to break down barriers in data, model, and computing power, and thus, realize the potential of AI to revolutionize drug discovery & development as a panelist at the “Personalized RegenMed Forum” hosted by Cellino on Thursday, November 14th.  This year’s forum will bring together scientific thought leaders, clinicians, patients and more to celebrate progress and collaborate on solutions to industry challenges faced while developing personalized regenerative medicine. To learn more or register for the forum, visit the event website here: https://bit.ly/4feqiZR #PRMForum2024 #CatalyzeCure

We’re excited to announce our collaboration with Accenture, leveraging both companies’ expertise in AI to significantly improve the efficiency of drug discovery and drive breakthroughs in therapeutic development for biopharma companies. Accenture’s deep experience in scaling AI solutions across enterprises, combined with 1910’s proprietary Input-Transform-Output (ITO™) platform, an end-to-end AI solution designed to deliver better drug candidates with applications across all modalities and therapeutic areas, will help break down barriers in data integration, modeling, and computing power. Together, we aim to accelerate the discovery and development of both small and large molecule therapeutics across the entire spectrum of therapeutic areas. Building on our existing partnership with Microsoft, this collaboration brings us closer to realizing the transformative potential of AI, empowering biopharma companies to deliver better drug candidates and overcome the historically high research and development failure rates. Learn more here: https://bit.ly/48qu5k9 #AI #DrugDiscovery #Biopharma #1910Genetics

We are excited to launch CANDID-CNS™, our AI model for predicting blood-brain barrier penetration and distribution, which achieves an 83% success rate versus a 64% success rate for the industry standard CNS-MPO score. Our state-of-the-art AI model holds the potential to revolutionize CNS drug discovery for diseases where fewer than 2% of small molecule drugs can cross the blood-brain barrier. With this announcement, we're also publishing the results of CANDID-CNS™ as a preprint on bioRxiv. CANDID-CNS™ is one of several frontier models within CANDID™, our proprietary multi-AI agent system which comprises several AI agents, each working in a task-oriented manner to solve the multiparameter optimization problem of drug discovery and predict the full set of drug-like characteristics required by the FDA to achieve a clinical CANDIDATE (hence, the model name, "CANDID"). CANDID-CNS™ is one of hundreds of proprietary models within our end-to-end Input-Transform-Output (ITO™) AI platform for drug discovery. We’re excited to continue unlocking the transformative possibilities of AI in our mission to enable pharmaceutical companies to overcome the high clinical failure rate of therapeutics. Learn more in the preprint and press release: Link to preprint: https://lnkd.in/gCbWV3wi Link to press release: https://bit.ly/4h7GUUs #neuroscience #bloodbrainbarrier #smallmolecules #leadoptimization #foundationmodels #AI #drugdiscovery #1910Genetics

Congratulations to Drs. David Baker, Demis Hassabis, and John Jumper for winning The Nobel Prize in Chemistry! This marks the second Nobel Prize for AI in 2 days! At 1910, our work in large molecule AI drug discovery began with AI-driven protein structure prediction. In 2018, tools like Rosetta were able to predict the N-terminal to C-terminal backbone structure of proteins but sometimes, not with high enough resolution to predict the conformations of the unique side chain attached to each amino acid. Protein structures are defined by hydropathic interaction (HINT) networks on multiple scales. These networks are hydrophobic as well as electrostatic/hydrogen bonding, and include favorable and unfavorable elements. Three-dimensional (3D) hydropathic interaction maps calculated by HINT encode these networks on a residue-by-residue basis. Importantly, these HINT maps can be clustered – reducing thousands of residue environments into ~18 maps on average – each with a unique side chain conformation and set of interactions. Through a 2019 collaboration with Dr. Glen Kellogg of Virginia Commonwealth University, 1910 developed a methodology for processing all 20 amino acids, thereby generating 12,000,000 HINT maps, yielding > 4,000 unique backbone maps and >10,000 unique side chain maps for about 800 total chess squares. This dataset was an unprecedented collection of information-rich 3D maps that encoded the hydropathic interaction environments favored by each amino acid residue. We then built AI and ML models to leverage our proprietary HINT map dataset for a variety of applications including side chain prediction, homology modeling, 3D protein structure prediction, and de novo protein design. With AlphaFold2, predicting both the structure of protein backbones and amino acid side chain conformations became possible, thereby solving a holy grail problem that was intractable for decades. While our work in large molecule AI drug discovery had roots in the prediction of protein side chain conformations, it has since expanded to include de novo design and optimization of large molecule therapeutics such as traditional monoclonal antibodies, Fabs, VHHs, antibody-drug conjugates, etc. Congratulations to Drs. Baker, Hassabis and Jumper for their well-deserved Nobel Prize, and for showing yet again, the tremendous promise of AI to revolutionize drug discovery!

Congratulations to Drs. Hopfield and Hinton for receiving The Nobel Prize in Physics for their groundbreaking work in machine learning and artificial neural networks. Their pioneering discoveries, including Hopfield Networks and the Boltzmann machine, have shaped the foundation of modern AI. We are proud to build upon these revolutionary advances, harnessing the power of AI to drive innovation in drug discovery and development. Their work continues to inspire our mission to unlock new possibilities in biopharma and improve patient outcomes through the transformative potential of AI.

Tomorrow, our Founder & CEO, Jen Nwankwo, Ph.D., will dive into the transformative potential of AI in biopharma during a fireside chat with Helen H. Liang, PhD of FoundersX Ventures at SF TECH WEEK by a16z. Don’t miss this exciting conversation on how we are leveraging cutting edge advancements in AI, such as agents and their underlying agentic systems to shape the future of drug discovery and development. Visit the event website to learn more or RSVP for the in-person event: https://bit.ly/4gUQDgA